.png){kind=icon}
.png){kind=icon}
Return
Comparative risk of hepatocellular carcinoma and mortality among initiators of GLP-1 receptor agonists versus other glucose-lowering therapies: a target trial emulation
.png){kind=icon}
OA
AI
J
O
S
D
X
D
A
J
L
S
D
DOI：10.1007/s12072-026-11138-9.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Glucagon-like peptide-1 receptor agonists (GLP-1 RA) may influence pathways involved in hepatocarcinogenesis, but evidence regarding their association with hepatocellular carcinoma (HCC) and mortality risk remains heterogeneous. We evaluated the association between GLP-1 RA initiation and HCC incidence compared with commonly used glucose-lowering medications, with secondary exploratory analyses of all-cause mortality following HCC diagnosis. We emulated active-comparator, new-user target trials using Patient-Centered Clinical Research Network data from UT Southwestern Medical Center (PCORnet–UTSW; 2010–2025). Adults with T2D initiating GLP-1 RA were compared with initiators of metformin, insulin, sodium–glucose cotransporter-2 inhibitors (SGLT2i), dipeptidyl peptidase-4 inhibitors (DPP4i), and sulfonylureas. The primary outcome was incident HCC; a secondary analysis evaluated all-cause mortality after HCC diagnosis. Five-year risks and risk differences under the intention-to-treat (ITT) approach were estimated using pooled logistic regression with inverse probability of treatment weighting. Per-protocol analyses accounted for treatment adherence using inverse probability of censoring weights. GLP-1 RA initiators had lower five-year HCC risk than comparator groups. Under ITT, risk differences were − 0.37% (95% CI − 0.59 to − 0.08) versus metformin, − 0.52% (95% CI − 0.74 to − 0.35) versus insulin, − 0.37% (95% CI − 0.70 to − 0.06) versus DPP4i, and − 0.39% (95% CI − 0.64 to − 0.13) versus sulfonylureas. Findings were stronger in per-protocol analyses and consistent across subgroups, sensitivity analyses and by individual GLP-1 RA agent. Mortality analyses were limited by small sample sizes but suggested a potential survival benefit. GLP-1 RA initiation was associated with lower HCC risk versus several comparators. Mortality findings were inconclusive and exploratory, warranting confirmation in larger studies.
Keywords:
GLP-1 receptor agonists
Hepatocellular carcinoma
Type 2 diabetes
Target trial emulation
New-user design
Mortality
Real-world data
Pharmacoepidemiology
Active-comparator
Journal
IF:
6.1
Papers:
2.1K
Citations:
5.9K
Organization
Cited Papers